drugset / Trial / NCT04655976
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Timeline
- Start
- 2020-12-08
- Primary completion
- 2025-06-05
- Completion
- 2027-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobolimab | Monoclonal antibody | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Dostarlimab | Monoclonal antibody | — | — |